Eli Lilly (LLY) Accounts Payables (2009 - 2026)

Eli Lilly has reported Accounts Payables for 18 years, with the latest figure at $5.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 46.11% year-over-year to $5.0 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (up 46.11% YoY), and the FY2025 full-year result was $5.4 billion, up 66.58% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.0 billion, down from $5.4 billion in the prior quarter.
• The five-year high for Accounts Payables was $5.4 billion in Q4 2025, with the low at $1.4 billion in Q1 2022.
• Historically, Accounts Payables has averaged $2.9 billion across 5 years, with a median of $2.6 billion in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables fell 12.58% — and 2025, when it jumped 66.58%.
• Eli Lilly's Accounts Payables stood at $1.9 billion in 2022, then jumped by 34.61% to $2.6 billion in 2023, then gained by 24.25% to $3.2 billion in 2024, then surged by 66.58% to $5.4 billion in 2025, then dropped by 6.51% to $5.0 billion in 2026.
• The last three Accounts Payables figures came in at $5.0 billion (Q1 2026), $5.4 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.